Compare Amphastar Pharmaceuticals Inc (AMPH) vs Morgan Stanley (MS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Morgan Stanley — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Morgan Stanley trades at $222.71 (market cap $350.60B). The key difference: Morgan Stanley is far larger — about 424.4× Amphastar Pharmaceuticals Inc's market cap, and Morgan Stanley pays a 1.8% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MS | |
|---|---|---|
Market Cap | $826.08M | $350.60B |
Sector | Health | Financials |
52-Week High | $30.81 | $227.19 |
52-Week Low | $16.87 | $139.09 |
Enterprise Value | $1.22B | — |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Morgan Stanley (MS) trades at $222.28, up 0.07% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $57.6B in 2024 to $66.0B in 2025 and net income reaching $16.9B. Recent earnings beats and selection to lead Anthropic's IPO highlight operational strength. Technical indicators show support at $220 and resistance at $224, with RSI suggesting mild overbought conditions.
Outlook remains positive with 53.85% analyst buy ratings and $225.80 consensus price target. Key opportunities include wealth management expansion and AI integration, while risks involve volatile cash flows and rising debt-to-asset ratios. The stock offers potential upside but requires monitoring of financial leverage and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
